Literature DB >> 8757190

Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma.

Y Takebayashi1, S Akiyama, S Akiba, K Yamada, K Miyadera, T Sumizawa, Y Yamada, F Murata, T Aikou.   

Abstract

BACKGROUND: Platelet-derived endothelial cell growth factor (PD-ECGF) is known to promote the development of new blood vessels, which are fundamental to tumor growth and metastasis. We previously found that thymidine phosphorylase (dThdPase) and PD-ECGF are the same protein.
PURPOSE: We retrospectively examined the expression of dThdPase in primary colorectal carcinomas, its association with angiogenesis and clinicopathologic findings, and its prognostic value.
METHODS: Tissues were obtained from the tumors of 163 patients whose colorectal carcinomas were completely removed by surgery. Microvessels assessed by immunostaining endothelial cells for factor VIII were counted on a 400x field in the most active areas of neovascularization within the tumor. We purified the monoclonal antibody against dThdPase and studied the expression of dThdPase in the same serial sections used for the detection of factor VIII. Those who carried out microvessel counting and dThdPase expression assessment had no knowledge of clinicopathologic findings. The significance of dThdPase in the prognosis of patients with colorectal carcinomas was also examined in the survival analysis of mortality follow-up data covering the period between 1984 through 1991. Reported P values are from two-sided tests of statistical significance.
RESULTS: The mean microvessel count (+/- standard deviation) in dThdPase-positive colorectal carcinoma specimens (17.5 +/- 7.2) was higher (P < .001) than that in dThdPase-negative carcinoma specimens (9.3 +/- 5.5). The dThdPase positivity was in accordance with the microvessel count. dThdPase positivity showed highly significant statistical associations with tumor size, extent of invasion, lymph node metastasis, lymphatic invasion, and venous invasion. Cox regression analysis revealed that dThdPase expression was prognostic for poor disease outcome after adjustment for Dukes' stage and microvessel count.
CONCLUSIONS: These findings suggest that higher levels of dThdPase expression in colorectal carcinomas are associated with more extensive angiogenesis, poor clinical and laboratory findings, and unfavorable clinical outcome. IMPLICATIONS: Inhibition of dThdPase in human colorectal carcinomas might improve prognosis for some patients.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8757190     DOI: 10.1093/jnci/88.16.1110

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  67 in total

Review 1.  Antiangiogenic therapy in human gastrointestinal malignancies.

Authors:  J Heidemann; D G Binion; W Domschke; T Kucharzik
Journal:  Gut       Date:  2006-10       Impact factor: 23.059

2.  Thymidine phosphorylase expression in progression of cervical cancer: correlation with microvessel count, proliferating cell nuclear antigen, and apoptosis.

Authors:  R Fujiwaki; K Hata; K Iida; Y Maede; M Koike; K Miyazaki
Journal:  J Clin Pathol       Date:  1999-08       Impact factor: 3.411

3.  Thymidilate synthase expression predicts longer survival in patients with stage II colon cancer treated with 5-flurouracil independently of microsatellite instability.

Authors:  Marisa Donada; Serena Bonin; Ermanno Nardon; Alessandro De Pellegrin; Giuliana Decorti; Giorgio Stanta
Journal:  J Cancer Res Clin Oncol       Date:  2010-04-13       Impact factor: 4.553

4.  Thymidine phosphorylase promotes metastasis and serves as a marker of poor prognosis in hepatocellular carcinoma.

Authors:  Qiang Zhang; Yang Zhang; Xuejiao Hu; Yuan Qin; Weilong Zhong; Jing Meng; Ting Xiao; Chunhong Zhang; Meng Li; Shuang Chen; Huijuan Liu; Yanrong Liu; Tao Sun; Cheng Yang
Journal:  Lab Invest       Date:  2017-05-22       Impact factor: 5.662

5.  Thymidine phosphorylase, dihydropyrimidine dehydrogenase and thymidylate synthase mRNA expression in primary colorectal tumors-correlation to tumor histopathology and clinical follow-up.

Authors:  Silke Lassmann; Michael Hennig; Robert Rosenberg; Jörg Nährig; Joachim Schreglmann; Friedemann Krause; Manuela Poignee-Heger; Hjalmar Nekarda; Heinz Höfler; Martin Werner
Journal:  Int J Colorectal Dis       Date:  2005-08-13       Impact factor: 2.571

6.  Prognostic significance of thymidine phosphorylase in superficial bladder carcinoma.

Authors:  N E Stavropoulos; C Bouropoulos; E Ioachim; M Michael; K Hastazeris; I Tsimaris; D Kalogeras; Z Liamis; V Kafarakis; S Stefanaki; V Malamou-Mitsi
Journal:  Int Urol Nephrol       Date:  2005       Impact factor: 2.370

Review 7.  Clinical significance of angiogenesis in gastrointestinal cancers: a target for novel prognostic and therapeutic approaches.

Authors:  Ronnie Tung-Ping Poon; Sheung-Tat Fan; John Wong
Journal:  Ann Surg       Date:  2003-07       Impact factor: 12.969

Review 8.  TAS-102: a novel antimetabolite for the 21st century.

Authors:  Nataliya Uboha; Howard S Hochster
Journal:  Future Oncol       Date:  2015-11-30       Impact factor: 3.404

9.  Targeted therapies in the management of colorectal carcinoma: role of bevacizumab.

Authors:  Ajithkumar Puthillath; Anush Patel; Marwan G Fakih
Journal:  Onco Targets Ther       Date:  2009-02-18       Impact factor: 4.147

10.  Prediction of sensitivity to fluoropyrimidines by metabolic and target enzyme activities in gastric cancer.

Authors:  Masanori Terashima; Hisataka Fujiwara; Akinori Takagane; Kaoru Abe; Takashi Irinoda; Tsutomu Nakaya; Hitoshi Yonezawa; Kenichi Oyama; Kazuyoshi Saito; Norio Kanzaki; Satoshi Ohtani; Tsuyoshi Nemoto; Yutaka Hoshino; Michihiko Kogure; Mitsukazu Gotoh
Journal:  Gastric Cancer       Date:  2003       Impact factor: 7.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.